Department of Gastrointestinal Surgery, Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao, China.
Department of Gastrointestinal Surgery, Shandong Provincial Hospital, Jinan, China.
Trials. 2021 Dec 11;22(1):912. doi: 10.1186/s13063-021-05887-1.
Gastric cancer, which is the fifth most common malignancy and the third most common cause of cancer-related death, is particularly predominant in East Asian countries, such as China, Japan and Korea. It is a serious global health issue that causes a heavy financial burden for the government and family. To our knowledge, there are few reports of multicentre randomized controlled trials on the utilization of CT angiography (CTA) for patients who are histologically diagnosed with gastric cancer before surgery. Therefore, we planned this RCT to verify whether the utilization of CTA can change the short- and long-term clinical outcomes.
The GISSG 20-01 study is a multicentre, prospective, open-label clinical study that emphasises the application of CTA for patients who will undergo laparoscopic gastrectomy to prove its clinical findings. A total of 382 patients who meet the inclusion criteria will be recruited for the study and randomly divided into two groups in a 1:1 ratio: the CTA group (n = 191) and the non-CTA group (n = 191). Both groups will undergo upper abdomen enhanced CT, and the CTA group will also receive CT angiography. The primary endpoint of this trial is the volume of blood loss. The second primary endpoints are the number of retrieved lymph nodes, postoperative recovery course, hospitalization costs, length of hospitalization days, postoperative complications, 3-year OS and 3-year DFS.
It is anticipated that the results of this trial will provide high-level evidence and have clinical value for the application of CTA in laparoscopic gastrectomy.
ClinicalTrials.gov , NCT04636099. Registered November 19, 2020.
胃癌是全球第五大常见恶性肿瘤和第三大癌症相关死亡原因,尤其在东亚国家如中国、日本和韩国较为高发。它是一个严重的全球健康问题,给政府和家庭带来了沉重的经济负担。据我们所知,针对术前组织学诊断为胃癌的患者,应用 CT 血管造影(CTA)的多中心随机对照试验报告较少。因此,我们设计了这项 RCT 来验证 CTA 的应用是否能改变患者的短期和长期临床结局。
GISSG 20-01 研究是一项多中心、前瞻性、开放标签的临床研究,重点关注 CTA 在接受腹腔镜胃切除术的患者中的应用,以证明其临床发现。符合纳入标准的 382 名患者将被纳入该研究,并以 1:1 的比例随机分为两组:CTA 组(n=191)和非 CTA 组(n=191)。两组均行上腹部增强 CT,CTA 组加行 CTA 检查。该试验的主要终点是出血量。次要主要终点是淋巴结检出数、术后恢复过程、住院费用、住院天数、术后并发症、3 年 OS 和 3 年 DFS。
预计该试验的结果将为腹腔镜胃切除术中 CTA 的应用提供高质量的证据和临床价值。
ClinicalTrials.gov,NCT04636099。于 2020 年 11 月 19 日注册。